Early Results of a BTK Degrader for Richter Transformation
May 8, 2026
In an early-stage clinical trial, half of patients with relapsed / refractory Richter transformation responded to treatment with BTK degrader BGB-16673.
In an early-stage clinical trial, half of patients with relapsed / refractory Richter transformation responded to treatment with BTK degrader BGB-16673.
Though it is still early, the combination of pirtobrutinib-venetoclax-obinutuzumab appears to have good efficacy in patients with Richter transformation.
Half of patients with Richter transformation responded to treatment with epcoritamab, and outcomes were even better when it was used as a first-line therapy.
Half of patients with Richter transformation responded to treatment with epcoritamab, and outcomes were even better when it was used as a first-line therapy.
Outcomes for patients with Richter transformation remain poor even with the introduction of targeted therapies.
Profiling the metabolites produced by cells in Richter transformation could help researchers develop new ways to target therapies in the future.
CAR-T therapy can be effective in certain patients with Richter transformation.
By never freezing the locally produced CAR-T cells, disappointing response rates for relapsed/refractory CLL and Richter’s Syndrome patients are greatly improved
Combination ibrutinib-venetoclax-obinutuzumab provided short-term control for patients with Richter’s transformation, but responses were not durable.